SCHEMBL20208532

SCHEMBL20208532

FC(F)(F)c1cnc2ccc(Cl)cn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.54
POLB P06746 1/20 0.47
FLT3 P36888 9/20 0.36
NRAS P01111 3/20 0.36
IRAK4 Q9NWZ3 3/20 0.36
FADS1 O60427 1/20 0.36
DYRK1A Q13627 1/20 0.35
DYRK2 Q92630 1/20 0.35
IRAK1 P51617 2/20 0.34
LCK P06239 1/20 0.34
RET P07949 1/20 0.34
PDGFRB P09619 1/20 0.34
CDK7 P50613 1/20 0.34
BLK P51451 1/20 0.34
CCNH P51946 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21305144 0.82 POLB (0.51) SCN5APOLBFLT3NRASIRAK4
SCHEMBL15639933 0.79 SCN5A (0.54) SCN5APOLBFLT3MEN1KMT2A
SCHEMBL28041698 0.75 POLB (0.54) POLBFLT3NRASIRAK4IRAK1
SCHEMBL22552094 0.75 SCN5A (0.50) SCN5ADYRK1ADYRK2TGFBR1
SCHEMBL20209265 0.75 SCN5A (0.69) SCN5AFLT3RETALDH1A1TGFBR1
SCHEMBL15638430 0.74 SCN5A (0.52) SCN5ATGFBR1
SCHEMBL3325146 0.72 POLB (0.51) POLBFLT3NRASIRAK4IRAK1
SCHEMBL16404632 0.72 POLB (0.56) POLBFLT3NRASIRAK4IRAK1
SCHEMBL3020269 0.72 POLB (0.51) POLBFLT3NRASIRAK4IRAK1
SCHEMBL21305142 0.71 POLB (0.44) SCN5APOLBFLT3NRASIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2021-06-24 US disclosed
WO-2018098500-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188839-A1 COMPOUNDS AND THEIR METHODS OF USE SCN1A, SCN3A, SCN1B SCN5A 8/4885POLB 4342/4885FLT3 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.